1. Chondroitin Sulfate Prevents STZ Induced Diabetic Osteoporosis through Decreasing Blood Glucose, AntiOxidative Stress, Anti-Inflammation and OPG/RANKL Expression Regulation
- Author
-
Hongxing Zheng, Shan Shan Qi, Yue Xin Zu, En Zhu Wang, and De Jing Chen
- Subjects
Blood Glucose ,0301 basic medicine ,Osteoporosis ,medicine.disease_cause ,Rats, Sprague-Dawley ,lcsh:Chemistry ,chemistry.chemical_compound ,0302 clinical medicine ,oxidative stress ,lcsh:QH301-705.5 ,Spectroscopy ,chondroitin sulfate ,biology ,Chondroitin Sulfates ,General Medicine ,Computer Science Applications ,RANKL ,diabetic osteoporosis ,030220 oncology & carcinogenesis ,Osteocalcin ,Immunohistochemistry ,Female ,bone-mineral density ,musculoskeletal diseases ,medicine.medical_specialty ,Article ,Catalysis ,Diabetes Mellitus, Experimental ,Proinflammatory cytokine ,Diabetes Complications ,Inorganic Chemistry ,03 medical and health sciences ,Internal medicine ,Diabetes mellitus ,medicine ,Animals ,Chondroitin sulfate ,Physical and Theoretical Chemistry ,Molecular Biology ,Inflammation ,business.industry ,RANK Ligand ,Organic Chemistry ,Osteoprotegerin ,medicine.disease ,Rats ,030104 developmental biology ,Endocrinology ,Gene Expression Regulation ,lcsh:Biology (General) ,lcsh:QD1-999 ,chemistry ,biology.protein ,business ,Oxidative stress - Abstract
Chondroitin sulfate (CS) has antioxidative, anti-inflammatory, anti-osteoarthritic and hypoglycemic effects. However, whether it has antidiabetic osteoporosis effects has not been reported. Therefore, in this study, we established a STZ-induced diabetic rat model, CS (500 mg kg&minus, 1 d&minus, 1) was orally administrated for eight weeks to study its preventive effects on diabetic osteoporosis. The results showed that eight weeks of CS treatment improved the symptoms of diabetes, the CS-treated group has increased body weight, decreased water or food intake, decreased blood glucose, increased bone-mineral density, repaired bone morphology and decreased femoral osteoclasts and tibia adipocytes numbers. After CS treatment, bone histomorphometric parameters returned to normal, the levels of serum inflammatory cytokines (IL-1&beta, IL-6 and TNF-&alpha, ) decreased significantly, serum SOD, GPX and CAT activities increased and MDA level increased. In the CS-treated group, the levels of serum ALP, CTX-1, TRACP 5b, osteocalcin and RANKL decreased and the serum RUNX 2 and OPG levels increased. Bone immunohistochemistry results showed that CS can effectively increase the expression of OPG and RUNX2 and reduce the expression of RANKL in diabetic rats. All of these indicate that CS could prevent STZ induced diabetic osteoporosis&mdash, mainly through decreasing blood glucose, antioxidative stress, anti-inflammation and regulation of OPG/RANKL expression. CS can therefore effectively prevent bone loss caused by diabetes.
- Published
- 2020
- Full Text
- View/download PDF